NOMID Safety

KINERET safety profile in NOMID patients

KINERET has a well-documented safety profile of clinical and patient experience in NOMID1,2

  • No patient permanently discontinued KINERET treatment due to ISRs, the majority of which were mild (76%) or moderate (24%)1
  • There were 24 serious adverse events (SAEs) reported in 14 of the 43 treated patients1,*
  • The most common adverse events associated with KINERET were ISRs1

*The most common SAEs were infections (a total of 13 infections in 7 patients, with pneumonia and gastroenteritis occurring in 3 and 2 patients, respectively. Five SAEs were related to lumbar puncture, which was a study procedure).1

A table showing the percentage of NOMID patients >10% reporting adverse events in the first 6 months of treatment with KINERET® (anakinra). Please review full Prescribing Information

Additional safety information1

  • In KINERET-treated NOMID patients, the risk of a disease flare when discontinuing KINERET treatment should be weighed against the potential risk of continued treatment. Do not initiate KINERET in patients with active infections
  • Use in combination with TNF-blocking agents is not recommended
  • Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported
  • The impact of treatment with KINERET on active and/or chronic infections and the development of malignancies is not known
  • Live vaccines should not be given concurrently with KINERET
  • Neutrophil counts should be assessed prior to initiating KINERET treatment, and while receiving KINERET, monthly for 3 months, and thereafter quarterly for a period up to 1 year